Featured Resource: Licensing deal with Stalicla SA & Clinical Programme update

Find out more about Evgen's licensing deal with Stalicla and about the current clinical programme Read More

October 12, 2022

Filter by:

Corporate Documents

Corporate Presentations

Scientific Posters & Presentations

Scientific Publications

Date

Title

Download

July 21, 2022

Voting on AGM Resolutions

June 21, 2022

Notice of AGM

July 13, 2021

Voting on AGM resolutions

June 17, 2021

Notice of AGM

February 2, 2021

2021 Placing form of proxy

February 2, 2021

2021 Placing and Open Offer shareholder circular

October 15, 2015

AIM Admission Document

October 12, 2015

Featured Resource: Licensing deal with Stalicla SA & Clinical Programme update

Corporate Documents

Corporate Presentations

Scientific Posters & Presentations

Scientific Publications

Voting on AGM Resolutions

Notice of AGM

Voting on AGM resolutions

Notice of AGM

2021 Placing form of proxy

2021 Placing and Open Offer shareholder circular

AIM Admission Document

Articles of Association

2022 Interim Results Presentation

Evgen Pharma Licensing and Clinical Programme Update

AGM Presentation – Harnessing the Power of Sulforaphane

Corporate Presentation – Harnessing the Power of Sulforaphane

Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer, presented at ESMO 2019 - Sacha Howell et al

Novel biomarkers for sulforaphane treated patients in ER+/HER- metastatic breast cancer, presented at ABPP 2019 - Daniel Conole et al

STEM Headline Results presentation, 25 March 2019 - Sacha Howell et al

STEM Trial: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer, presented at the San Antonio Breast Cancer Symposium 2018 - Sally Ross et al

SFX-01 targets STAT3 signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours, presented at the UK Interdisciplinary Breast Cancer Symposium 2018 - Bruno Simoes et al

Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma, Pharmaceuticals, 26 October 2021 - Alessandro Colapietro et al

Effect of SFX-01 on proliferation of human glioblastoma cell lines, BioRxiv, 16 September 2021 - Euphemia Leung et al

Can Activation of NRF2 Be a Strategy against COVID-19? Trends in Pharmacological Sciences, September 2020 - Antonio Cuadrado et al

Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer, Nature Oncogene, 20 May 2020 - Bruno Simoes et al

Final Results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC), Annals of Oncology, 1 October 2019 - Sacha Howell et al

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Nature Reviews Drug Discovery, 5 February 2019 - Antonio Cuadrado et al

Sulforaphane treatment of autism spectrum disorder (ASD), PNAS, 28 October 2014 - Kanwaljit Singh et al